Table 1.
Baseline characteristics of all participants according to TyG index tertiles
| Variables | Total | TyG index | P-value | ||
|---|---|---|---|---|---|
| Tertile 1 | Tertile 2 | Tertile 3 | |||
| N | 231 | 77 | 77 | 77 | |
| General information | |||||
| Age, year | 81.58 ± 1.93 | 81.49 ± 1.69 | 81.77 ± 2.23 | 81.47 ± 1.84 | 0.576 |
| Female, n (%) | 75 (32.47%) | 14 (18.18%) | 28 (36.36%) | 33 (42.86%) | 0.003 |
| Height, cm | 165.41 ± 8.06 | 166.55 ± 8.03 | 165.17 ± 8.40 | 164.51 ± 7.71 | 0.276 |
| Weight, kg | 67.96 ± 11.30 | 68.04 ± 11.89 | 68.12 ± 11.20 | 67.71 ± 10.93 | 0.972 |
| BMI, kg/m2 | 24.78 ± 3.42 | 24.44 ± 3.45 | 24.94 ± 3.62 | 24.96 ± 3.20 | 0.574 |
| SBP, mmHg | 139.19 ± 21.57 | 139.58 ± 18.36 | 143.10 ± 22.03 | 134.90 ± 23.49 | 0.060 |
| DBP, mmHg | 69.77 ± 12.06 | 69.64 ± 10.74 | 70.38 ± 12.31 | 69.31 ± 13.16 | 0.855 |
| LVEF, % | 56.28 ± 9.19 | 58.26 ± 7.82 | 55.87 ± 9.55 | 54.72 ± 9.84 | 0.051 |
| Current smoking, n (%) | 67 (29.00%) | 27 (35.06%) | 21 (27.27%) | 19 (24.68%) | 0.335 |
| Laboratory markers | |||||
| eGFR, mL/min/1.73 m2 | 69.12 ± 20.94 | 72.76 ± 19.90 | 68.75 ± 21.27 | 65.85 ± 21.31 | 0.121 |
| FBG, mmol/L | 8.51 ± 6.06 | 5.92 ± 1.68 | 7.75 ± 2.23 | 11.85 ± 9.21 | < 0.001 |
| UA, umol/L | 354.50 ± 200.08 | 361.12 ± 306.02 | 343.06 ± 97.01 | 359.33 ± 133.73 | 0.828 |
| TC, mmol/L | 4.03 ± 0.99 | 3.69 ± 0.91 | 4.06 ± 0.95 | 4.35 ± 1.01 | < 0.001 |
| TG, mmol/L | 1.50 ± 0.77 | 0.93 ± 0.29 | 1.38 ± 0.32 | 2.21 ± 0.88 | < 0.001 |
| LDL-C, mmol/L | 2.26 ± 0.85 | 2.00 ± 0.73 | 2.33 ± 0.86 | 2.43 ± 0.89 | 0.004 |
| HDL-C, mmol/L | 1.09 ± 0.36 | 1.19 ± 0.47 | 1.09 ± 0.29 | 0.98 ± 0.26 | 0.002 |
| TyG index | 9.01 ± 0.67 | 8.30 ± 0.32 | 8.99 ± 0.16 | 9.75 ± 0.43 | < 0.001 |
| History of Past Illness | |||||
| Hypertension, n (%) | 200 (86.58%) | 68 (88.31%) | 65 (84.42%) | 67 (87.01%) | 0.770 |
| Previous stroke, n (%) | 51 (22.08%) | 21 (27.27%) | 17 (22.08%) | 13 (16.88%) | 0.299 |
| Previous MI, n (%) | 35 (15.15%) | 10 (12.99%) | 15 (19.48%) | 10 (12.99%) | 0.431 |
| Hyperlipidemia, n (%) | 56 (24.24%) | 20 (25.97%) | 16 (20.78%) | 20 (25.97%) | 0.686 |
| CKD, n (%) | 37 (16.02%) | 11 (14.29%) | 11 (14.29%) | 15 (19.48%) | 0.598 |
| Cardiovascular medications | |||||
| Aspirin, n (%) | 227 (98.27%) | 75 (97.40%) | 76 (98.70%) | 76 (98.70%) | 0.775 |
| Clopidogrel, n (%) | 220 (95.24%) | 75 (97.40%) | 72 (93.51%) | 73 (94.81%) | 0.513 |
| Statin, n (%) | 213 (92.21%) | 72 (93.51%) | 68 (88.31%) | 73 (94.81%) | 0.282 |
| β-blocker, n (%) | 154 (66.67%) | 53 (68.83%) | 52 (67.53%) | 49 (63.64%) | 0.776 |
| ACEI/ARB, n (%) | 145 (62.77%) | 49 (63.64%) | 48 (62.34%) | 48 (62.34%) | 0.982 |
| Angiography | |||||
| LAD lesion, n (%) | 195 (84.42%) | 69 (89.61%) | 66 (85.71%) | 60 (77.92%) | 0.126 |
| LCX lesion, n (%) | 150 (64.94%) | 50 (64.94%) | 53 (68.83%) | 47 (61.04%) | 0.598 |
| RCA lesion, n (%) | 169 (73.16%) | 56 (72.73%) | 54 (70.13%) | 59 (76.62%) | 0.658 |
| LM lesion, n (%) | 35 (15.15%) | 9 (11.69%) | 15 (19.48%) | 11 (14.29%) | 0.390 |
| Multivessel lesion, n (%) | 180 (77.92%) | 61 (79.22%) | 61 (79.22%) | 58 (75.32%) | 0.797 |
| Gensini score | 55.44 ± 41.43 | 46.55 ± 29.80 | 58.52 ± 43.33 | 61.25 ± 48.01 | 0.064 |
| Treatment | 0.176 | ||||
| Intensive medication, n (%) | 79 (34.20%) | 31 (40.26%) | 24 (31.17%) | 24 (31.17%) | |
| PCI | 145 (62.77%) | 45 (58.44%) | 48 (62.34%) | 52 (67.53%) | |
| CABG | 7 (3.03%) | 1 (1.30%) | 5 (6.49%) | 1 (1.30%) | |